Innovent Biologics rises on robust Q1 product revenue growth

China Renaissance Holdings

02/05/2025 03:37

** Shares of Innovent Biologics Inc 1801.HK rise 2.8% to HK$55.25 on their second session of gain, on track for the biggest one-day pct gain since April 24

** The Chinese innovative medicines developer and producer says it achieved total product revenue exceeding 2.4 bln yuan ($330.10 mln) for the first quarter of 2025, maintaining over 40% year-on-year growth

** "The year 2025 is a significant year for the company as it enters a new era of growth and global innovation" - Innovent

** Hang Seng Biotech Index .HSHKBIO gains 0.8%, Hang Seng Index .HSI rises 1.5%

** Stock up 50.7% YTD

($1 = 7.2706 Chinese yuan renminbi)

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))